Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) today announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide. Danegaptide is a novel Zealand invented dipeptide with potential as a first-in-class medicinal treatment to reduce tissue damage caused by reperfusion.
Help employers find you! Check out all the jobs and post your resume.
